期刊文献+

大孔吸附树脂分离纯化棘白霉素B母核的工艺研究 被引量:1

Separation and Purification of Echinocandin B Nucleus by Macroporous Adsorption Resin
下载PDF
导出
摘要 研究了大孔吸附树脂分离纯化棘白霉素B母核(ECBN)的工艺条件。以大孔吸附树脂D303为脱色树脂、HZ835为吸附树脂,将ECBN滤液pH值调至5.5进行吸附,吸附量为14 512μg·mL^(-1);再以5%乙醇水溶液为解吸剂解吸,解吸率为91.8%;最后经纳滤浓缩、脱炭、结晶、真空干燥等工艺得到ECBN粗粉,含量为65%左右,色谱纯度大于80%,提取总收率超过60%。该工艺简单易行、操作成本低、溶媒消耗少,适合工业化生产。 We studied the separation and purification conditions of Echinocandin B nucleus (ECBN) by macroporous adsorption resin.Using resin D303 as a decolorization resin,resin HZ835 as an adsorption resin,and 5% ethanol aqueous solution as a desorbent,the ECBN (pH=5.5) is dynamically adsorbed and desorbed with an adsorption capacity of 14 512 μg·mL ^-1 and a desorption rate of 91.8%,respectively.Then,through nanofiltration concentration,decarbonization,crystallization,and vacuum drying,we obtained ECBN crude powder with the content of about 65%,the purity of more than 80%,and the total yield of more than 60%.The process has the advantages of simple operation,low cost,low solvent consumption,which is suitable for industrial production.
作者 彭亮 王晶珂 谢新宇 李敏 PENG Liang;WANG Jingke;XIE Xinyu;LI Min(National Engineering Research Center of Microbial Medicine,Hebei Industry Microbial Metabolic Engineering & Technology Research Center,New Drug Research and Development Co.,Ltd.,North China Pharmaceutical Corporation,Shijiazhuang 050015,China)
出处 《化学与生物工程》 CAS 2019年第4期10-12,23,共4页 Chemistry & Bioengineering
基金 国家"重大新药创制"科技专项(2014ZX09201001-002)
关键词 棘白霉素B母核 大孔吸附树脂 分离纯化 Echinocandin B nucleus macroporous adsorptionresin separation and purification
  • 相关文献

参考文献4

二级参考文献59

  • 1Julia Lynch,Annie Wong-Beringer,席瑜钦.卡泊芬净引起严重可逆性血小板减少[J].中国处方药,2005,4(2):75-77. 被引量:4
  • 2曹国颖,傅得兴.新型棘白菌素类抗真菌药阿尼芬净[J].中国新药杂志,2005,14(11):1358-1361. 被引量:15
  • 3陈頔,曹国颖,傅得兴,孙春华.棘白霉素类抗真菌药的研究进展[J].中国新药杂志,2007,16(14):1082-1087. 被引量:15
  • 4DEBONO M, GORDEE RS. Antibiotics that inhibit fungai cell wall development [ J ]. Annu Rev Microbiol, 1994, 48 ( 12 ) : 471 - 497.
  • 5MURDOCH D, PLOSKER GL. Anidulafungin[ J]. Drug, 2004, 64 (19) :2249 - 2258.
  • 6TAWARA S, IKEDA F, MAKI K, et al. In vitro activities of a new lipopeptide antifungal agent micafungin against a variety of clinically important fungi[ J]. Antimicrob Agents Chemother, 2000,44 (1) :57 -62.
  • 7ESPINEL-INGROFF A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK20991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [ J ]. Clin Microbiol, 1998, 36 (10) : 2950 - 2956.
  • 8BARCHIESI F,SPREGHINI E,TOMASSETTI S, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis [ J ]. A ntimicrob Agents Chemother , 2006,50 ( 8 ) :2719 - 2727.
  • 9CACCIAPUOTI A, HALPERN J, MENDRICK C, et al. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic AspergiUus infection [ J]. Antimicrob Agents Chemother, 2006,50 (7) : 2587 - 2590.
  • 10VERWEIJ PE, OAKLEY KL, MORRISSEY J, et al. Efficacy of LY303366 against amphotericin B susceptible and resistant Aspergillus fumigatus in a murine model of invasive aspergil losis[ J]. Antimicrob Agents Chemother, 1998, 42 (4) : 873 - 878.

共引文献38

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部